GSK Sets Out Liver Disease Research for AASLD

GSK has outlined research on chronic hepatitis B, metabolic dysfunction-associated steatohepatitis and alcohol-related liver disease for the American Association for the Study of Liver Diseases meeting in Denver. The company's announcement covers follow-up data on bepirovirsen, marketed as Hibsago, and findings and trial plans for investigational efimosfermin. The programmes address different treatment settings and include different kinds of study endpoints. GSK Press Releases report.

Liver Research Spans Three Disease Areas

GSK will present data from its liver portfolio at the American Association for the Study of Liver Diseases The Liver Meeting 2026, taking place in Denver, Colorado, from 5 to 9 November. The company says the 21 abstracts cover chronic hepatitis B, metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver disease.

The presentations mix approved-product evidence, investigational phase II readouts and trial-in-progress descriptions. GSK frames the collection as reinforcing a pipeline to improve patient outcomes across chronic liver disease. The sections below separate the assets by regulatory status and by the endpoints the disclosed abstracts describe.

Hibsago (bepirovirsen): Approved in US and Japan

Bepirovirsen, marketed as Hibsago, is approved in the US and Japan, following what GSK describes as recent US Food and Drug Administration approval. GSK licensed bepirovirsen from Ionis and collaborated with it on development.

The AASLD material rests largely on the B-Well phase III programme. An oral presentation will report functional cure rates 48 weeks after all chronic hepatitis B virus treatment is stopped in virologically suppressed patients.

Efimosfermin: Investigational, Phase II and Phase III

Efimosfermin remains investigational. GSK describes it as a once-monthly subcutaneous injection of a long-acting FGF21 variant designed to regulate metabolic pathways to decrease liver fat, reduce inflammation and reverse fibrosis in MASH and alcohol-related liver disease. It holds Breakthrough Therapy Designations from the US FDA and China's CDE, and PRIME designation from the European Medicines Agency for MASH.

A phase II open-label poster will report results up to 52 weeks on non-invasive markers of liver fibrosis in participants with moderate to advanced fibrosis or compensated cirrhosis (F2 to F4), with GSK describing an acceptable safety profile. A second phase II analysis examines the association between liver fat reduction and histological fibrosis improvement in F2 to F3 patients.

Why Regulatory Status Differs Between the Two Assets

GSK describes bepirovirsen as approved in the US and Japan, while efimosfermin remains investigational. Bepirovirsen presentations include B-Well phase III results, long-term durability follow-up in the B-Sure study and quality-of-life observations in complete responders. Efimosfermin presentations include phase II findings and descriptions of ongoing phase III trials.

GSK also sets out the treatment landscape it is targeting. It states existing chronic hepatitis B therapies can suppress the virus but many patients often require lifelong therapy. It states MASH treatments approved under accelerated or conditional pathways are indicated for moderate to advanced liver fibrosis, and no approved options exist for more advanced MASH.

What This Means for Practitioners

For clinicians, the distinction is practical. Bepirovirsen evidence at this meeting concerns functional cure rates after treatment cessation, predictors of response and retreatment modelling in patients who relapse, all in an approved product context. Efimosfermin evidence concerns non-invasive fibrosis markers, liver fat and safety in phase II, with phase III endpoints still being generated. Findings should be read as exploratory signals rather than established clinical benefit.

Our recommendation for investors and pipeline watchers is to evaluate each presentation on its own study design, rather than interpreting conference participation as a new approval or an immediate commercial outcome. Practitioners evaluating either programme should track the specific endpoints, trial phases and regulatory designations attached to each abstract, and treat GSK's framing of unmet need as the company's own assessment.